Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting
-Daily chart shows many signs of dilution (upside wicks, price closing weak when volume present)
-Price pumped $1 in PM
-Backside right off the open, clear downtrend, below VWAP all day
-Levels: 2.40, 2.60, 3
Trade 1: First Test short of 2.40 zone
Trade 2: First Test short of 2.25 zone
Trades were good, first was successful, second was a scratch.
You need to log into your Tradervue account to leave a comment. If you don't have one,
it takes just a few seconds to sign up, and it's free!
You can write your trade notes and comments using markdown syntax for links, images, etc. Some quick examples to get you started:
For other options, see Markdown syntax documentation.
Note that normal HTML tags are not supported in Tradervue.